A Subgroup Analysis of Chinese Patients Switched to Paliperidone Palmitate One-Month Injectable by Prior Oral Antipsychotic Treatment

作者：Si, T.; Fan, J.; Wang, X.; Wang, C.; Xu, C.; Zhuo, J.; Feng, Y.^*

来源：Pharmacopsychiatry, 2016, 49(1): 32-41.

DOI：10.1055/s-0035-1565133

• antipsychotic
• Chinese patients
• long-acting injectable
• paliperidone palmitate
• schizophrenia

Introduction: Safely tapering current antipsychotic medication, while balancing efficacy and tolerability, is an important consideration when switching patients from their antipsychotic therapy to a new treatment. The efficacy and tolerability of paliperidone palmitate one-month (PP1M) in Chinese patients switched from previous antipsychotic treatments were examined in order to develop effective switching and dosing strategies.
Methods: A 13-week open-label, single arm, prospective, interventional study was conducted in Chinese patients (n=610) with acute schizophrenia to examine their response, by previous treatment group, when switched to PP1M (75-150mg eq).
Results: Among 610 patients with 30% reduction in PANSS total score were 191/263 (72.6%) risperidone/paliperidone extended-release patients, 36/52 (69.2%) olanzapine patients, and 214/293 (73.0%) other antipsychotic patients. Patient functioning and adherence were significantly (p0.05) improved for all subgroups.
Discussion: Patients on higher doses of prior antipsychotics generally took longer to withdraw from their current medication. Most patients were administered the 100mg eq dose, and all subgroups received a similar mean dose (114-119mg eq) of PP1M. Recommendations for transitioning patients to PP1M from each subgroup are discussed.

• 出版日期2016-1
• 单位北京大学; 汕头大学; 上海市精神卫生中心; 河北医科大学